Radiolabeled albumin technetium tc-99m albumin colloid kit - Biologic Drug Details

✉ Email this page to a colleague

Summary for radiolabeled albumin technetium tc-99m albumin colloid kit

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for radiolabeled albumin technetium tc-99m albumin colloid kit Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for radiolabeled albumin technetium tc-99m albumin colloid kit Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for radiolabeled albumin technetium tc-99m albumin colloid kit Derived from Patent Text Search

No patents found based on company disclosures

Radiolabeled albumin technetium tc-99m albumin colloid kit Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Radiolabeled Albumin Tc-99m Albumin Colloid Kits?

The global market for radiolabeled albumin Tc-99m albumin colloid kits is driven by diagnostic imaging applications, particularly shunt patency, liver/spleen imaging, and tumor localization. The key factors shaping the market include technological advances, regulatory policies, hospital adoption rates, and the competitive landscape.

Market Drivers

Growing demand for diagnostic imaging: Tc-99m radiopharmaceuticals account for approximately 80% of all nuclear medicine procedures worldwide. Tc-99m’s favorable half-life (6 hours) and gamma emission make it suitable for imaging.
Increasing prevalence of liver and spleen diseases: Conditions such as cirrhosis, hepatocellular carcinoma, and splenic disorders require diagnostic imaging. The use of albumin colloid kits enhances imaging accuracy in these cases.
Advancements in kit formulations: Improved stability, ease of use, and production processes further facilitate market adoption. Innovations range from lyophilized kits to ready-to-use formulations.
Rising healthcare infrastructure investment: Growth in nuclear medicine departments in emerging markets expands the user base.

Market Challenges

Regulatory hurdles: Approval processes for radiopharmaceuticals are lengthy and vary across regions. Stringent safety and efficacy standards can delay market entry.
Limited shelf life: Tc-99m kits require proximity to a cyclotron or reactor (for Mo-99 supply), involving logistics constraints that affect availability and waste.
Competition from alternative agents: Other imaging agents, such as Tc-99m sulfur colloid or newer PET tracers, influence market share.

Market Size and Growth

Estimated valuation of the global radiolabeled albumin Tc-99m colloid kit market was approximately USD 200–250 million in 2022.
Compound annual growth rate (CAGR) projected at 4–6% through 2030, driven by expanding diagnostic procedures and technological improvements.

What Is the Financial Trajectory for Radiolabeled Albumin Tc-99m Albumin Colloid Kits?

Revenue Streams and Pricing Models

Pricing: Kits typically range from USD 100 to USD 400 per dose, depending on region, regulatory status, and manufacturer. High volumes and local manufacturing reduce costs.
Sales channels: Primarily sold through direct hospital supply agreements, with some distribution via radiopharmacies.

Key Financial Factors

Production costs: Include raw materials (kits are lyophilized), manufacturing, and radiolabeling logistics. The cost of Mo-99 supply impacts overall expenses significantly.
Market penetration: Adoption in hospitals, especially in emerging markets, increases sales volume. Mature markets are influenced by regulatory approvals and replacing older agents with newer formulations.
Reimbursement landscape: Reimbursement policies vary; favorable reimbursement can boost sales, while limits hinder growth.

Financial Outlook

Revenue projections: Expect revenues to grow at a CAGR of 4–6%. For a mid-sized manufacturer generating USD 100 million annually, this could mean an additional USD 4–6 million yearly by 2030.
Profitability margins: Typically moderate in this segment, around 10–20%, influenced by manufacturing scale, R&D investments, and regulatory costs.
Investment focus: Companies are investing in R&D for kit stabilization, faster imaging protocols, and expanding into emerging markets.

How Do Regulatory Policies Impact the Market and Financial Outlook?

Regional regulatory agencies—such as the U.S. FDA, European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA)—enforce standards on safety, efficacy, and manufacturing quality.

Regulatory Landscape

Approval processes: Require extensive documentation, clinical trials, and stability data. Approval timelines span from 6 months to several years.
Reimbursement policies: Influence market penetration; countries with comprehensive coverage support higher sales volume.
Good Manufacturing Practice (GMP): Strict adherence affects manufacturing costs but ensures market access.

Market Implications

Regulatory barriers increase time-to-market and costs, which can suppress short-term revenue growth.
Approved, well-regulated kits allow higher reimbursement rates, supporting sustained revenue.

Summary and Strategic Considerations

The radiolabeled albumin Tc-99m colloid kit market is poised for steady growth driven by rising demand for nuclear medicine diagnostics and technological improvements.
Challenges remain in regulatory approval, logistics, and competition from alternative agents.
Financially, market participants should focus on optimizing production costs, expanding into emerging markets, and maintaining compliance to secure reimbursement.

Key Takeaways

The market size is approximately USD 200–250 million, with a 4–6% CAGR forecast through 2030.
Growth factors include rising disease prevalence, technological innovation, and healthcare infrastructure expansion.
Market hurdles involve regulatory approval times, limited shelf life, and competition from other imaging agents.
Reimbursement policies and regional regulations significantly influence revenue trajectories.
Profitability margins depend on production efficiency and market penetration strategies.

FAQs

1. What are the main applications of radiolabeled albumin Tc-99m kits?
They are primarily used for liver, spleen, and shunt imaging, as well as tumor localization in nuclear medicine.

2. How does the supply of Mo-99 affect this market?
As the parent isotope for Tc-99m, Mo-99 supply issues can cause shortages, impacting kit availability and sales.

3. What regions are emerging markets for these kits?
Asia-Pacific, Latin America, and Africa are expanding markets due to increasing healthcare infrastructure investment.

4. How do regulatory differences influence market entry?
Stringent standards and approval processes can extend time-to-market and increase costs, affecting competitiveness.

5. Are there innovations expected in the near future?
Yes, developments include lyophilized formulations for longer shelf life, integrated kits for rapid imaging, and alternative radiolabeling techniques.

References

[1] MarketsandMarkets. "Nuclear Medicine Market by Product, Application, and Region — Global Forecast to 2027," 2022.

More… ↓

⤷ Start Trial